Cardiothoracic & vascular anesthesia
Assessing the impact of different heparin dosing regimens for cardiopulmonary bypass on anticoagulation: the HepDOSE pilot study
Authors' conclusion
This pilot study indicates that, while larger heparin dosing for routine cardiac surgery results in subtle biochemical changes in coagulation, there is no demonstrable benefit in postoperative blood loss or transfusion requirements.
Study context
- Population
- Patients undergoing routine elective cardiac surgery on cardiopulmonary bypass (CPB) in a single tertiary cardiac centre
- Participants
- 60 patients
- Comparison
- Initial heparin dose 300 vs 400 vs 500 U/kg before CPB
- Primary endpoint
- Postoperative blood loss and transfusion
- Follow-up
- First 24 hr after surgery
Methodological detailsprospective, single-centre
- Prospective
- Single-centre
Primary result
As reported in the abstract
Blood loss and transfusion · 24 hr
- No difference in overall blood loss, packed RBC transfusion or other blood product transfusion
Secondary outcomes
Total administered heparin dose
Fibrinopeptide A (FPA), fibrinopeptide B (FPB), D-dimer
- No statistically significant differences at the measured time intervals
Thrombin-antithrombin (TAT) complexes
- Trend towards lower TAT on CPB with greater heparin dosing; statistically significant after protamine
Original publication
Assessing the impact of different heparin dosing regimens for cardiopulmonary bypass on anticoagulation: the HepDOSE pilot study. Can J Anaesth. Published 20 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →